Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension
Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension
复制标题
DOI：
10.1016/j.actbio.2014.05.031
复制
发表时间：
2014-10-01
影响因子：
9.7
通讯作者：
Liu, Catherine Jui-ling
中科院分区：
文献类型：
--
作者：
Cheng, Yung-Hsin;Hung, Kuo-Hsuan;Liu, Catherine Jui-ling
青光眼是一种不可逆的眼部疾病，可导致进行性视野丧失，最终导致失明，眼内压（IOP）控制不佳。拉坦前列素是最有效的眼部消肿化合物之一，是目前青光眼的一线治疗药物。然而，每日滴注所需的疗效和不良副作用是治疗依从性失败和持续性青光眼治疗的主要原因。在本研究中，我们开发了一种可注射的温敏性壳聚糖/明胶/磷酸甘油（C/G/GP）水凝胶作为拉坦前列素的缓释系统用于青光眼治疗。负载拉坦前列素的C/G/GP水凝胶可在37 ° C下在1分钟内胶凝。结果表明，拉坦前列素从C/G/GP水凝胶在体外和体内的持续释放。载拉坦前列素的C/G/GP水凝胶显示出良好的体内外生物相容性。采用玻璃体内注射曲安奈德建立兔青光眼模型。在单次结膜下注射负载拉坦前列素的C/G/GP水凝胶后，IOP在8天内显著降低，然后保持在正常水平。本研究结果提示，拉坦前列素负载C/G/GP水凝胶可能在青光眼治疗中具有潜在的应用。(C)2014 Acta Materialia Inc.由爱思唯尔有限公司出版。保留所有权利。
Glaucoma is an irreversible ocular disease that may lead to progressive visual field loss and eventually to blindness with inadequately controlled intraocular pressure (IOP). Latanoprost is one of the most potent ocular hypotensive compounds, the current first-line therapy in glaucoma. However, the daily instillation required for efficacy and undesirable side-effects are major causes of treatment adherence failure and persistence in glaucoma therapy. In the present study, we developed an injectable thermosensitive chitosan/gelatin/glycerol phosphate (C/G/GP) hydrogel as a sustained-release system of latanoprost for glaucoma treatment. The latanoprost-loaded C/G/GP hydrogel can gel within 1 min at 37 degrees C. The results show a sustained release of latanoprost from C/G/GP hydrogel in vitro and in vivo. The latanoprost-loaded C/G/GP hydrogel showed a good in vitro and in vivo biocompatibility. A rabbit model of glaucoma was established by intravitreal injection of triamcinolone acetonide. After a single subconjunctival injection of latanoprost-loaded C/G/GP hydrogel, IOP was significantly decreased within 8 days and then remained at a normal level. The results of the study suggest that latanoprost-loaded C/G/GP hydrogel may have a potential application in glaucoma therapy. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.